Merck: Zepatier beats Sovaldi regimen in Phase III study

Merck & Co. Inc. (NYSE:MRK) said efficacy and safety of Zepatier grazoprevir/elbasvir were superior to Sovaldi sofosbuvir plus peginterferon and ribavirin in the Phase III C-EDGE Head-to-Head study to treat HCV

Read the full 316 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE